The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...

Roche has shared new data from its Alzheimer’s disease (AD) development portfolio at this year’s Alzheimer’s Association ...

There are currently estimated to be 982,000 people with some form of dementia, including Alzheimer's in the UK ...

A breakthrough new drug could halt the progression of Alzheimer's disease, claim researchers. Trials suggest the drug—called ...

A new drug cleared 91% of brain amyloid plaques in 7 months, showing faster results than current Alzheimer's treatments and advancing to Phase III trials in 2025.

Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F.

Cognition Therapeutics’ dementia drug showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients ...

Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate ...

A new Alzheimer’s drug has been hailed as a major breakthrough after clinical trials showed it could clear the harmful brain ...

Roche has added a phase 3 trial of trontinemab, hoping to show it can delay or prevent progression to Alzheimer's symptoms in preclinical patients.

Eisai is launching a special dementia discovery centre to boost development of next-generation medicines targeting forms of the condition, including Alzheimer’s disease. The new Center for ...